Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Sep 26, 2014 (12 years ago)

Venlafaxine Hydrochloride Extended-Release Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications; 12 month stability time point

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Venlafaxine Hydrochloride Extended-Release Tablets, 37.5 mg, 30-count bottles and 90-count bottles, RX only, Manufactured for Sun Pharma Global Inc. Dubai, United Arab Emirates by Sun Pharmaceutical Industries Limited, Halol, India

Drug: Venlafaxine Category: Mental Health Medication

Recalling firm
Sun Pharma Global Inc.
Origin
N/A, United Arab Emirates
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0236-2015 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Venlafaxine recalls

See all
Class II · Moderate risk

Venlafaxine Tablets

Presence of Foreign Substance: Product complaint received for the presence of foreign material embedded resembling a metal shaving in one tablet.

Completed Particulate / foreign matter Zydus Pharmaceuticals (USA) Inc NDC 68382-021-01 D-0310-2025
Class II · Moderate risk

Venlafaxine Hydrochloride

Failed dissolution specifications: out of specification result obtained during routine stability testing for high dissolution.

Terminated Dissolution failure The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-7075-61 D-0584-2024
Class II · Moderate risk

Venlafaxine Tablets

Presence of Forein Tablets/Capsules; Venlafaxine Tablets, USP 37.5 mg found in bottles labeled as Venlafaxine Tablets, USP, 50 mg

Terminated Labeling / mix-up Sun Pharmaceutical Industries INC NDC 16714-657-01 D-0703-2021

Other dissolution failure recalls from 2014

All dissolution failure recalls
Class II · Moderate risk

Mercaptopurine Tablets

Failed USP Dissolution Test Requirements: This sub-recall is in response to Prometheus Laboratories Inc. recall for Mercaptopurine USP 50mg because the lot does not meet the specification for dissolution.

Terminated Dissolution failure American Health Packaging NDC 68084-325-21 D-0300-2015
Class II · Moderate risk

Mercaptopurine Tablets

Failed Dissolution Specifications: Product found to be out of specification (OOS) during stability testing.

Terminated Dissolution failure Prometheus Laboratories Inc. NDC 49884-922-02 D-0249-2015
Class II · Moderate risk

Bystolic (nebivolol)

Failed Dissolution Specification; at the 6-month stability time point

Terminated Dissolution failure Forest Pharmaceuticals Inc NDC 0456-1420-07 D-0036-2015
Class II · Moderate risk

Tarceva (erlotinib)

Failed Dissolution Specifications: The product did not meet the acceptance criteria for the dissolution test during the 24 month routine stability testing.

Terminated Dissolution failure Astellas Pharma US Inc NDC 50242-064-01 D-0008-2015